Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 5/20 | 0.41 |
| ▸ | ALPI | P09923 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 2/20 | 0.33 |
| ▸ | ALPG | P10696 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381259 | 0.84 | MAPT (0.37) | HDAC1HDAC2ADORA2AADORA1ADORA3 | |
| SCHEMBL2850900 | 0.77 | HDAC1 (0.44) | HDAC1HDAC2 | |
| SCHEMBL2846026 | 0.73 | ADA (0.51) | ADAALPIHDAC1HDAC2NPC1 | |
| SCHEMBL2843175 | 0.72 | ADORA2A (0.49) | HDAC1ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL2847129 | 0.66 | ADORA2A (0.41) | HDAC1HDAC2ADORA2AMAPT | |
| SCHEMBL8285072 | 0.65 | ADA (0.58) | ADAALPIHDAC1ADORA2AADORA1 | |
| SCHEMBL21659301 | 0.64 | ADA (0.85) | ADAALPIADORA2AADORA1ALPL | |
| SCHEMBL14019391 | 0.64 | ADORA2A (0.50) | HDAC1ADORA2AADORA1 | |
| SCHEMBL872184 | 0.62 | ADA (0.46) | ADAALPINPC1RAB9AADORA2A | |
| SCHEMBL14922346 | 0.62 | ADORA2A (0.62) | HDAC1NPC1RAB9AADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723343-B2 | Adenosine A2A receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7691869-B2 | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2129220-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | King Pharmaceuticals Research and Development Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008121748-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT,INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242672-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242673-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242672-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | ADA 44/4885ALPI 556/4885HDAC1 4098/4885 |
| US-20080242673-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | ADA 44/4885ALPI 556/4885HDAC1 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.